Results 181 to 190 of about 33,060 (236)

Performance of large language models in answering frequently‐asked questions on celiac disease

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Celiac disease (CeD) is a common autoimmune condition requiring lifelong adherence to a gluten‐free diet (GFD). Patients and caregivers increasingly seek information online, and large language models (LLMs) have emerged as potential educational tools. However, their reliability in CeD remains uncertain.
Nadav Peled   +6 more
wiley   +1 more source

Personalized AZithromycin/metronidAZole + dietary therapy in pediatric Crohn disease: Results of a pilot study

open access: yes
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Charlotte M. Verburgt   +15 more
wiley   +1 more source

Body composition at 2 years of age in moderate and late preterm infants

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Moderate and late preterm infants (MLPTI, gestational age 32 0/7–36 6/7 weeks) have altered body composition compared to term‐born infants, but data beyond infancy are lacking. This study aimed to assess body composition at 2 years corrected age for prematurity (CA) in MLPTI, compare it to the literature on term‐born infants, and ...
Anne H. Lafeber   +6 more
wiley   +1 more source

A novel diagnostic serum protein signature for pediatric inflammatory bowel disease

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Diagnostic delay is common in pediatric inflammatory bowel disease (PIBD), and fecal calprotectin (FCP) is often limited by challenges with sample collection. Therefore, we aimed to identify and validate a blood‐based diagnostic protein signature of PIBD.
Charlotte Bache‐Wiig Mathisen   +22 more
wiley   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy